A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 52
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : ORRs
Long Form : overall response rates
No. Year Title Co-occurring Abbreviation
2020 Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. axi-cel, CAR, CR, CRP, CRS, DLBCL, ICANS, OS, PFS, R/R, tisa-cel
2020 Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study. HMAs, MDS, PFS
2020 Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma. NDMM, OS, PFS, VGPR
2020 Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis. AEs, AIHA, CI, CRRs, HA, MAHA, RRs, RTX
2019 A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. ASCT, BuMel, MCL, OS, PFS
2019 A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. CI, CLL, CR, HRs, OS, PFS, R/R, VEN
2019 A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas. CHOPE, CR, OS, PFS, PTCLs
2019 Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis. CI, DCRs, HRs, NSCLC, ORs, PFS, RRs
2019 Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases. DCRs, iPFS, NSCLC, OS, PFS, PP
10  2019 Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. DARA, DaraPomD, MM, PFS, POM, PRs
11  2019 Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. STS
12  2019 Early chemotherapy de-escalation strategy in patients with advanced-stage Hodgkin lymphoma with negative positron emission tomography scan after 2 escalated BEACOPP cycles. CR, HL, OS, PET2, PFS
13  2019 Efficacy and safety of Levetiracetam as adjunctive treatment in children with focal onset seizures: A systematic review and meta-analysis. ADR-related, CIs, FOS, LEV, RRs, TEAE
14  2019 Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Elderly Patients with Metastatic Breast Cancer: A Meta-Analysis. CI, ECOG, MBC, nab-paclitaxel, OR
15  2019 Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer. CBRs, HR, PFS
16  2019 Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. CBR, DEX, FDA, LEN, mAbs, MM, POM
17  2019 Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies. non-Sq, NSCLC, OS, PD-1, SQ
18  2018 A Phase Ib study of ruxolitinib + gemcitabine nab-paclitaxel in patients with advanced solid tumors. AEs, JAK, MTDs, STAT
19  2018 Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a single-centre analysis. MSS, PFS
20  2018 Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. DOT, IMDC, IO, mRCC, OS, PD-L1
21  2018 Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis. DCRs, NMA, NSCLC, OS, PFS
22  2018 Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis. BCCs, SHHis
23  2018 Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. ET, JAK2, MF, MPNs, PK, PV
24  2018 Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio. mOS, mTTF, mUC, NLR
25  2017 Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer. CRC, DCRs, FF, FTU, IROX, ORs, PFS, RCTs, SUCRA
26  2017 Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. LDH, PD-1, peCTLs, RECIST v1.1
27  2017 Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). AEs, OS, RECIST v1.1
28  2017 Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. CMML, MDS
29  2016 Evaluation of effects of thymidylate synthase and excision repair cross-complementing 1 polymorphisms on chemotherapy outcome in patients with gastrointestinal tumors using peripheral venous blood. ERCC1, TYMS
30  2016 Pembrolizumab (Keytruda). NSCLC
31  2016 Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective. MBC, MT, OS, sb-paclitaxel
32  2015 Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials. CI, CRPC, HR, MTAs, OS, PFS, RCTs, RR, RR, RR
33  2015 Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome. CR, mCR, MDS, PCR, PR, WT
34  2015 Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma. CLL, SLL
35  2015 Variability in the anti-tumor effect of tegafur-uracil depending on histologic types of lung cancer. DCRs, LC, NSCLC, OS, PFSs, SQ, TS
36  2014 Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. CAs, CR, FISH, ISS, LDH, MM, nCR, OS, PR, UHR, VGPR
37  2014 Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. BORT, LEN, LoDEX, OS, PFS, POM, RRMM
38  2013 Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer. AGC, PR, RECIST, RECIST 1.1, SD
39  2013 FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. LAPC
40  2012 Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer. NSCLC
41  2012 Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. CI, HR, MTAs, OS, PC, PFS, RCTs
42  2011 Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. MBC, PFS
43  2010 Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. NSCLC, PD, PR, RECIST, SD, TKIs
44  2010 Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. MM, OS, PFS
45  2008 The role of UFT in advanced gastric cancer. 5-FU, OS
46  2005 Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. NSCLC, QOL, TTP
47  2005 Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. ---
48  2002 Docetaxel in advanced gastric cancer. ---
49  2001 Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Bcl-2, BM, PB
50  2000 Role of epirubicin in advanced breast cancer. CR, FEC
51  1999 Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies. 5-FU
52  1999 Irinotecan in cancers of the lung and cervix. NSCLC, SCLC